References

  1. Kourlaba G, Dimopoulos MA, Pectasides D, et al. Comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with breast cancer. Supportive Care Cancer. 2015; 23(7): 2045–2051.
  2. Pelgraz® Summary of Product Characteristics (SmPC)
  3. Chirivella I, Bermejo B, Insa A, et al. Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. Breast Cancer Res Treat. 2009; 114:479-484.
  4. Holmes FA, Jones SE, O’Shaughnessy J, et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Annals of Oncology. 2002; 13(6): 903–909.
  5. Barni S, Lorusso V, Giordano M, et al. A prospective observational study to evaluate G-CSF usage in patients with solid tumors receiving myelosuppressive chemotherapy in Italian clinical oncology practice. Med Oncol. 2014;31(1):797.
  6. Desai K, Misra P, Kher S, et al. Clinical confirmation to demonstrate similarity for a biosimilar pegfilgrastim: a 3-way randomized equivalence study for a proposed biosimilar pegfilgrastim versus US-licensed and EU-approved reference products in breast cancer patients receiving myelosuppressive chemotherapy Exp Hematol Oncol (2018) 7:22, https://doi.org/10.1186/s40164-018-0114-9
  7. Biosimilars in the EU. Information guide for healthcare professionals. European Medicines Agency. 2017. http://www.ema.europa.eu/docs/en_GB/document_library/Leaflet/2017/05/WC500226648.pdf
  8. Singh I, Patel A, Patel R, et al. Pharmacokinetic and pharmacodynamic bioequivalence study of a pegfilgrastim biosimilar INTP5 in healthy subjects. Cancer Chemotherapy and Pharmacology. 2018. https://doi.org/10.1007/s00280-018-3620-x .
  9. Desai K, Catalano T, Rai G, et al. Confirmation of Biosimilarity in a Pharmacokinetic/Pharmacodynamic Study in Healthy Volunteers for an Analytically Highly Similar Pegfilgrastim. Clinical Pharmacology in Drug Development. 2016; 5(5): 354–363.
  10. Assessment based on: Prevention from Sharps Injuries in the Hospital and Healthcare Sector. Implementation Guidance for the EU Framework Agreement. Available at: www.europeanbiosafetynetwork.eu/resources